Vestcor Inc Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

Vestcor Inc acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 799 shares of the health services provider’s stock, valued at approximately $73,000.

Other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI raised its holdings in Amedisys by 119.0% during the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after buying an additional 30,213 shares during the last quarter. ABC Arbitrage SA acquired a new position in Amedisys during the fourth quarter worth $2,522,000. Geode Capital Management LLC raised its holdings in Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after buying an additional 7,071 shares during the last quarter. Quarry LP acquired a new position in Amedisys during the third quarter worth $2,569,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Amedisys by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after buying an additional 9,004 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Performance

NASDAQ AMED opened at $92.50 on Wednesday. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 1.78 and a beta of 0.76. The company has a fifty day moving average price of $92.17 and a 200-day moving average price of $92.67.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. As a group, equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.